-
UPDATE: BMO Capital Markets Reiterates on Masimo Following Mixed 3Q13 Results
Thursday, October 31, 2013 - 10:25am | 153Read More...In a report published Thursday, BMO Capital Markets analyst Joanne K. Wuensch reiterated a Market Perform rating on Masimo (NASDAQ: MASI), and raised the price target from $22.00 to $24.00. In the report, BMO Capital Markets noted, “MASI reported 3Q13 results that missed slightly on the top line,...
-
UPDATE: BMO Capital Markets Reiterates on Endologix Following Stronger 3Q13 Estimates
Thursday, October 31, 2013 - 10:23am | 178Read More...In a report published Thursday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on Endologix (NASDAQ: ELGX), and raised the price target from $18.00 to $20.00. In the report, BMO Capital Markets noted, “ELGX reported 3Q13 estimates that were better than expected,...
-
UPDATE: BMO Capital Markets Downgrades NuVasive on Multiple Positive Factors
Monday, July 15, 2013 - 10:16am | 150Read More...In a report published Monday, BMO Capital Markets analyst Joanne K. Wuensch downgraded NuVasive (NASDAQ: NUVA) from Market Perform to Underperform, but raised the price target from $18.00 to $22.00. In the report, BMO Capital Markets noted, “We are downgrading shares of NUVA to Underperform...
-
UPDATE: BMO Capital Raises PT on Wright Medical Group on Renewed Focus
Monday, July 8, 2013 - 10:59am | 114Read More...In a report published on Friday, BMO Capital Markets analyst Joanne K. Wuensch raised the price target on Wright Medical Group (NASDAQ: WMGI) from $26 to $31 and reiterated an Outperform rating. In the report, BMO Capital Markets noted, "On its own, without Augment (which is not in our model),...
-
UPDATE: BMO Capital Markets Raises PT on CareFusion Citing Adherence to Corporate Strategy
Monday, July 8, 2013 - 10:31am | 129Read More...In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on CareFusion (NYSE: CFN) and raised the price target from $38 to $41. In the report, BMO Capital Markets noted, "We reiterate our Outperform rating on shares of CFN. The stock has run...
-
UPDATE: BMO Capital Markets Lowers PT on Covidien Ahead of Mallinckrodt Spin-Off
Friday, June 28, 2013 - 9:21am | 165Read More...In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on Covidien (NYSE: COV), but lowered the price target from $72.00 to $64.00. In the report, BMO Capital Markets noted, “Covidien management has provided a tremendous amount of detail to...
-
UPDATE: BMO Capital Markets Raises PT on The Cooper Companies Following FY2Q13 Results
Friday, June 7, 2013 - 1:35pm | 135Read More...In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on The Cooper Companies (NYSE: COO), and raised the price target from $120.00 to $130.00. In the report, BMO Capital Markets noted, “COO reported FY2Q13 results that missed on the top line,...
-
NuVasive, Inc.’s (NUVA) Fourth-Quarter Review
Friday, February 26, 2010 - 5:35pm | 102Read More...Analysts Joanne K. Wuensch and Lyndsey A. Miller at BMO Capital Markets have released a report reviewing the fourth-quarter results at NuVasive, Inc. (NASDAQ: NUVA). The company reported revenue of $106.9 million for the quarter, which is an increase of 43.4% over the same period last year. The...
